報價延遲最少15分鐘:2025/05/13 13:48 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.61 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.55/0.36
|
|
企業價值
289.58M
|
| 資產負債 |
|
每股賬面淨值
0.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 13:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |